The findings that MED12 depletion causes resistance of BRCA-deficient cells to chemotherapeutic agents, prompted us to explore if MED12 levels have any impact on the tumor response to genotoxic chemotherapy, in clinical samples. Here, MED12 is linked to neoplasm.